Abstracts tagged "Cholesterol"

Abstract Number: 1543 • 2013 ACR/ARHP Annual Meeting
Patients With Ankylosing Spondylitis Are Substantially Undertreated For Hypertension and Hypercholesterolemia
Sjoerd C. Heslinga^1,2,3, Inge A.M. van den Oever¹, Alper M. van Sijl^2,4, Irene E. Van der Horst-Bruinsma^4,5 and Michael. T. Nurmohamed^2,4, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Internal Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with ankylosing spondylitis (AS) have a decreased life expectancy due to an increased cardiovascular (CV) risk. The general inflammatory process is held responsible…
Abstract Number: 1398 • 2013 ACR/ARHP Annual Meeting
Comparison Of Atherogenicity Of Plasma From Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Beenish Hafiz¹, Iryna Voloshyna², Michael J. Littlefield², Steven E. Carsons³, Elise Belilos¹, Kristina Belostocki¹, Lois A. Bonetti⁴, Gary C. Rosenblum¹ and Allison B. Reiss², ¹Rheumatology, Winthrop University Hospital, Mineola, NY, ²Medicine, Winthrop University Hospital, Mineola, NY, ³Div of Rheumatology, Winthrop University Hospital, Mineola, NY, ⁴Rheum & Immun, Winthrop University Hospital, Mineola, NY
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are immune mediated inflammatory disorders linked to increased risk of cardiovascular disease (CVD), mostly due to accelerated…
Abstract Number: 1407 • 2013 ACR/ARHP Annual Meeting
High Serum Cholesterol Predicts Rheumatoid Arthritis In Women
Carl Turesson¹, Ulf Bergström², Mitra Pikwer², Jan-Åke Nilsson² and Lennart Jacobsson², ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Patients with active rheumatoid arthritis (RA) tend to have low cholesterol levels due to effects of inflammation on lipid metabolism. However, several prospective studies…
Abstract Number: 766 • 2013 ACR/ARHP Annual Meeting
Cholesterol Accumulation By Synovial Lining Macrophages Results In Ectopic Bone Formation During Experimental Osteoarthritis
Wouter de Munter¹, Arjen B. Blom¹, Monique M. Helsen¹, Birgitte Walgreen¹, Peter M. van Der Kraan¹, Leo A. Joosten², Wim B. van den Berg³ and Peter L. van Lent⁴, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, ⁴Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Synovial macrophages have previously shown to play a significant role in the etiopathology of experimental collagenase-induced osteoarthritis (OA). In addition to production of pro-inflammatory…
Abstract Number: 2515 • 2012 ACR/ARHP Annual Meeting
Low Density Lipoprotein Receptor Deficiency Results in Osteophyte Formation During Experimental Osteoarthritis Which Is Enhanced Under High Cholesterol Conditions
Wouter de Munter, Birgitte Walgreen, Monique M. Helsen, Annet W. Sloëtjes, Wim B. van den Berg and Peter L.E.M. van Lent, Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Synovial macrophages are involved in osteophyte formation during experimental collagenase-induced osteoarthritis (OA). Accumulated LDL can be oxidized in an inflammatory environment such as OA…
Abstract Number: 2157 • 2012 ACR/ARHP Annual Meeting
Resveratrol Counters Pro-Atherogenic Effects of Systemic Lupus Erythematosus and Rheumatoid Arthritis Plasma On Cholesterol Efflux in Human Macrophages
Allison B. Reiss¹, Iryna Voloshyna¹, Ofek Hai¹, Michael J. Littlefield¹, Elise Belilos², Kristina B. Belostocki², Lois A. Bonetti³, Gary C. Rosenblum² and Steven E. Carsons⁴, ¹Medicine, Winthrop University Hospital, Mineola, NY, ²Rheumatology, Winthrop University Hospital, Mineola, NY, ³Rheum & Immun, Winthrop University Hospital, Mineola, NY, ⁴Div of Rheumatology, Winthrop University Hospital, Mineola, NY
Background/Purpose: Our group has demonstrated that resveratrol, a plant polyphenol, possesses atheroprotective properties, enhancing expression of reverse cholesterol transport (RCT) proteins. We have reported that Systemic…
Abstract Number: 1290 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis
Christina Charles-Schoeman¹, Roy Fleischmann², Jean Davignon³, Howard Schwartz⁴, Scott Turner⁵, Carine Beysen⁵, Mark Milad⁶, Zheng Luo⁷, John Bradley⁸, Irina Kaplan⁸, Richard Riese⁷, Andrea Zuckerman⁷ and Iain B. McInnes⁹, ¹University of California, Los Angeles, CA, ²Metroplex Clinical Research Center, Dallas, TX, ³University of Montreal, Montreal, Canada, ⁴Miami Research Associates, Miami, FL, ⁵KineMed Inc., Emeryville, CA, ⁶Milad Pharmaceutical Consulting LLC, Plymouth, MI, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc, Groton, CT, ⁹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In RA patients (pts), suppression…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].